Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting

Rhea-AI Summary

BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX) announced its participation in the 46th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO) from February 11–15, 2023, in Orlando, Florida. The company will present findings related to its gene therapy programs, including new data on its lead candidate, DB-OTO, and interim results from the Phase 1b trial of DB-020 for cisplatin chemotherapy patients. Presentations will be made by Kathryn Ellis, Ph.D., and John Lee, among others, covering various aspects of gene therapy and its applications for hearing loss and ototoxicity.

BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present findings from its drug discovery and development programs at the 46^th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held in Orlando, Florida February 11–15, 2023.

The Company will present new data on its lead investigational gene therapy product candidate, DB-OTO, as well as new data across its gene therapy pipeline. Decibel will also present additional data from the interim analysis of the Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy.

Podium Presentations

Podium 1 | Precise Targeting of GJB2 Cells Results in Safe and Efficacious Gene Therapy in a Rodent Model of Hearing Loss Due to GJB2 Deficiency
Presenter: Kathryn Ellis, Ph.D.
Session Title: Gene Therapy
Date & Time: Saturday, February 11, 2:00 – 4:00 p.m. ET

Podium 26 | Development of DB-020, a Locally Administered Product for Protection Against Cisplatin-Induced Ototoxicity
Presenter: John Lee
Session Title: Cisplatin Ototoxicity
Date & Time: Tuesday, February 14, 10:30 a.m. – 12:30 p.m. ET

Poster Presentations

SU83 | Development of a Platform for Parallel Functional Evaluation of Cell Type Specific Synthetic Promoters for Gene Therapy

SU84 | Dual Vector Gene Therapy Approaches for STRC-Related Hearing Loss

MO83 | Nonclinical Pharmacology, Biodistribution, and Safety Studies Supporting the Clinical Development of DB-OTO (AAV1-Myo15-hOTOFv5) for Hearing Loss Due to Genetic Otoferlin Protein Deficiency

TU83 | Development of a Utricle Culture System for Exploring Dual AAV-Mediated Expression Kinetics of Human Otoferlin

TU232 | Advancing Bioinformatically Informed Targets to Achieve In Vivo Vestibular Regeneration

About Decibel Therapeutics
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy product candidate, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of creating a world of connection for people with hearing and balance disorders. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow us on Twitter.

Investor Contact:
Julie Seidel
Stern IR, Inc.
212-362-1200
Julie.seidel@sternir.com

Media Contact:
Chris Railey
Ten Bridge Communications
617-834-0936
chris@tenbridgecommunications.com

FAQ

What is Decibel Therapeutics presenting at the ARO Annual Meeting 2023?

Decibel Therapeutics will present findings on its gene therapy programs, including new data on DB-OTO and interim results from the Phase 1b clinical trial of DB-020.

When is Decibel Therapeutics presenting at the ARO Annual Meeting?

Decibel Therapeutics will be presenting from February 11 to February 15, 2023.

What is DB-OTO?

DB-OTO is Decibel Therapeutics' lead investigational gene therapy product candidate aimed at treating congenital, monogenic hearing loss.

What is DB-020 used for?

DB-020 is being developed to protect against cisplatin-induced ototoxicity in chemotherapy patients.

Who are the presenters for Decibel Therapeutics at the ARO Meeting?

Kathryn Ellis, Ph.D., and John Lee will present findings on gene therapy and cisplatin ototoxicity.